Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hoperam-CT
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hoperam-CT is an oral fixed-dose combination therapy developed by Zinnia Life Sciences for the treatment of hypertension and cardiovascular disease. It contains two active pharmaceutical ingredients: ramipril and chlorthalidone. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing blood pressure. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits the Na+-Cl- cotransporter (NCC/SLC12A3) in the distal convoluted tubule of the kidney, leading to increased excretion of sodium and water and a subsequent reduction in plasma volume. The combination of these two mechanisms provides a synergistic effect for blood pressure management.
- Brand names
- Hoperam-CT
- Other names
- ramipril + chlorthalidoneRamipril and Chlorthalidone
02
Targets
ACE (Angiotensin Converting Enzyme)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on Hoperam-CT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hoperam-CT.